MedTrace Logo

Humoral and Cellular Immune Response to COVID-19 Vaccines in Immunocompromised and Healthy Individuals

NCT04858607 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 373

Last updated 2023-02-09

No results posted yet for this study

Summary

Currently, the efficacy of COVID-19 vaccination in immunodeficient patients is unknown. Here the investigators aim to evaluate the efficacy of COVID-19 vaccines in immunodeficient patients compared to healthy controls. The investigators will assess the humoral and cellular response to COVID-19 vaccination in these subjects in detail. Furthermore, factors associated with good response to vaccination will be identified. The results of this study will help to guide future recommendations on COVID-19 vaccination in this population.

Conditions

  • Covid19
  • Immunosuppression

Interventions

DIAGNOSTIC_TEST

Blood sample

Serology, immune status, T cell immunity, and T cell aging.

DIAGNOSTIC_TEST

Saliva sample

Antibody tests

Sponsors & Collaborators

  • Medical University of Graz

    lead OTHER

Principal Investigators

  • Martin Stradner, Prof. · Medical University of Graz

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-19
Primary Completion
2023-01-20
Completion
2023-01-20

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04858607 on ClinicalTrials.gov